Since there is evidence for estrogen and estrogen-like compounds to have beneficial effect
on the pathogenesis of hepatocellular carcinoma (HCC), this study was designed to …

Background/Aims: Tamoxifen has previously been shown to prolong the survival of patients
with advanced stages of hepatocellular carcinoma and it has been suggested that it inhibits …

This study aimed to examine the role of estrogen receptor (ER)‐α36 in the metastasis of
hepatocellular carcinoma (HCC) and in the epithelial‐mesenchymal transition (EMT). HCC …

Erlotinib, an EGFR tyrosine kinase inhibitor has been introduced into cancer chemotherapy.
However, the therapeutic effects of erlotinib in hepatocellular carcinoma (HCC) remain …

Abstract Cytochrome P450‐2E1 (CYP2E1) is one of the major hepatic enzymes involved in
the metabolism of procarcinogen. Our study aimed to investigate the differential expression …

Abstract Cytochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1) catalyze the oxidative
metabolism of 17β-estradiol (E2) to catechol estrogens (2-OHE2 and 4-OHE2) and estrogen …

Hepatocarcinoma cancer (HCC), one of the most malignant cancers, occurs significantly
more often in men than in women; however, little is known about its underlying molecular …

Cytochrome P450s (P450s) contribute to carcinogenesis by activating procarcinogens and
also metabolize anti-cancer drugs. The activity and protein levels of P450s are important in …

Background & Aims Patients with cirrhosis are at high risk for hepatocellular carcinoma
(HCC) and often have increased serum levels of estrogen. It is not clear how estrogen …

Previous studies have reported that estrogen receptors (ERs) are expressed in normal
human liver, chronic hepatitis, and benign hepatic tumor tissues. However, decreased …